VEGFR (vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes

Karla B. Neves, Francisco J. Rios, Lucas Van Der Mey, Rheure Alves-Lopes, Alan C. Cameron, Massimo Volpe, Augusto C. Montezano, Carmine Savoia, Rhian M. Touyz

Research output: Contribution to journalArticle

Abstract

Although VEGF (vascular endothelial growth factor) inhibitors (VEGFIs), are effective anticancer therapies, they cause hypertension through unknown mechanisms. We questioned whether changes in vascular redox state may be important, because VEGF signaling involves nitric oxide (NO) and reactive oxygen species. Molecular mechanisms, including NOS, NADPH oxidase (Nox)-derived reactive oxygen species, antioxidant systems, and vasoconstrictor signaling pathways, were probed in human endothelial cells and vascular smooth muscle exposed to vatalanib, a VEGFI. Vascular functional effects of VEGFI were assessed ex vivo in mouse arteries. Cardiovascular and renal in vivo effects were studied in vatalanib-or gefitinib (EGFI [epidermal growth factor inhibitor])-treated mice. In endothelial cells, vatalanib decreased eNOS (Ser1177) phosphorylation and reduced NO and H2O2 production, responses associated with increased Nox-derived O2 - and ONOO- formation. Inhibition of Nox1/4 (GKT137831) or Nox1 (NoxA1ds), prevented vatalanib-induced effects. Nrf-2 (nuclear factor erythroid 2-related factor 2) nuclear translocation and expression of Nrf-2-regulated antioxidant enzymes were variably downregulated by vatalanib. In human vascular smooth muscles, VEGFI increased Nox activity and stimulated Ca2+ influx and MLC20 phosphorylation. Acetylcholine-induced vasodilatation was impaired and U46619-induced vasoconstriction was enhanced by vatalanib, effects normalized by N-acetyl-cysteine and worsened by L-NAME. In vatalanib-, but not gefitinib-treated mice vasorelaxation was reduced and media:lumen ratio of mesenteric arteries was increased with associated increased cardiovascular and renal oxidative stress, decreased Nrf-2 activity and downregulation of antioxidant genes. We demonstrate that inhibition of VEGF signaling induces vascular dysfunction through redox-sensitive processes. Our findings identify Noxs and antioxidant enzymes as novel targets underling VEGFI-induced vascular dysfunction. These molecular processes may contribute to vascular toxicity and hypertension in VEGFI-treated patients.

Original languageEnglish
Pages (from-to)638-647
Number of pages10
JournalHypertension
Volume71
Issue number4
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Vascular Endothelial Growth Factor Receptor
Vascular Endothelial Growth Factor A
Oxidation-Reduction
Blood Vessels
NADPH Oxidase
Antioxidants
Vascular Smooth Muscle
Vasodilation
Reactive Oxygen Species
Nitric Oxide
Down-Regulation
Endothelial Cells
Phosphorylation
Hypertension
Kidney
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Mesenteric Arteries
NG-Nitroarginine Methyl Ester
Vasoconstrictor Agents
Enzymes

Keywords

  • Endothelial cells
  • Gefitinib
  • Reactive oxygen species
  • Vasodilation
  • Vatalanib

ASJC Scopus subject areas

  • Internal Medicine

Cite this

VEGFR (vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes. / Neves, Karla B.; Rios, Francisco J.; Van Der Mey, Lucas; Alves-Lopes, Rheure; Cameron, Alan C.; Volpe, Massimo; Montezano, Augusto C.; Savoia, Carmine; Touyz, Rhian M.

In: Hypertension, Vol. 71, No. 4, 01.04.2018, p. 638-647.

Research output: Contribution to journalArticle

Neves, KB, Rios, FJ, Van Der Mey, L, Alves-Lopes, R, Cameron, AC, Volpe, M, Montezano, AC, Savoia, C & Touyz, RM 2018, 'VEGFR (vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes', Hypertension, vol. 71, no. 4, pp. 638-647. https://doi.org/10.1161/HYPERTENSIONAHA.117.10490
Neves, Karla B. ; Rios, Francisco J. ; Van Der Mey, Lucas ; Alves-Lopes, Rheure ; Cameron, Alan C. ; Volpe, Massimo ; Montezano, Augusto C. ; Savoia, Carmine ; Touyz, Rhian M. / VEGFR (vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes. In: Hypertension. 2018 ; Vol. 71, No. 4. pp. 638-647.
@article{9c3128e042aa49509e709233e88b36ab,
title = "VEGFR (vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes",
abstract = "Although VEGF (vascular endothelial growth factor) inhibitors (VEGFIs), are effective anticancer therapies, they cause hypertension through unknown mechanisms. We questioned whether changes in vascular redox state may be important, because VEGF signaling involves nitric oxide (NO) and reactive oxygen species. Molecular mechanisms, including NOS, NADPH oxidase (Nox)-derived reactive oxygen species, antioxidant systems, and vasoconstrictor signaling pathways, were probed in human endothelial cells and vascular smooth muscle exposed to vatalanib, a VEGFI. Vascular functional effects of VEGFI were assessed ex vivo in mouse arteries. Cardiovascular and renal in vivo effects were studied in vatalanib-or gefitinib (EGFI [epidermal growth factor inhibitor])-treated mice. In endothelial cells, vatalanib decreased eNOS (Ser1177) phosphorylation and reduced NO and H2O2 production, responses associated with increased Nox-derived O2 - and ONOO- formation. Inhibition of Nox1/4 (GKT137831) or Nox1 (NoxA1ds), prevented vatalanib-induced effects. Nrf-2 (nuclear factor erythroid 2-related factor 2) nuclear translocation and expression of Nrf-2-regulated antioxidant enzymes were variably downregulated by vatalanib. In human vascular smooth muscles, VEGFI increased Nox activity and stimulated Ca2+ influx and MLC20 phosphorylation. Acetylcholine-induced vasodilatation was impaired and U46619-induced vasoconstriction was enhanced by vatalanib, effects normalized by N-acetyl-cysteine and worsened by L-NAME. In vatalanib-, but not gefitinib-treated mice vasorelaxation was reduced and media:lumen ratio of mesenteric arteries was increased with associated increased cardiovascular and renal oxidative stress, decreased Nrf-2 activity and downregulation of antioxidant genes. We demonstrate that inhibition of VEGF signaling induces vascular dysfunction through redox-sensitive processes. Our findings identify Noxs and antioxidant enzymes as novel targets underling VEGFI-induced vascular dysfunction. These molecular processes may contribute to vascular toxicity and hypertension in VEGFI-treated patients.",
keywords = "Endothelial cells, Gefitinib, Reactive oxygen species, Vasodilation, Vatalanib",
author = "Neves, {Karla B.} and Rios, {Francisco J.} and {Van Der Mey}, Lucas and Rheure Alves-Lopes and Cameron, {Alan C.} and Massimo Volpe and Montezano, {Augusto C.} and Carmine Savoia and Touyz, {Rhian M.}",
year = "2018",
month = "4",
day = "1",
doi = "10.1161/HYPERTENSIONAHA.117.10490",
language = "English",
volume = "71",
pages = "638--647",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - VEGFR (vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes

AU - Neves, Karla B.

AU - Rios, Francisco J.

AU - Van Der Mey, Lucas

AU - Alves-Lopes, Rheure

AU - Cameron, Alan C.

AU - Volpe, Massimo

AU - Montezano, Augusto C.

AU - Savoia, Carmine

AU - Touyz, Rhian M.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Although VEGF (vascular endothelial growth factor) inhibitors (VEGFIs), are effective anticancer therapies, they cause hypertension through unknown mechanisms. We questioned whether changes in vascular redox state may be important, because VEGF signaling involves nitric oxide (NO) and reactive oxygen species. Molecular mechanisms, including NOS, NADPH oxidase (Nox)-derived reactive oxygen species, antioxidant systems, and vasoconstrictor signaling pathways, were probed in human endothelial cells and vascular smooth muscle exposed to vatalanib, a VEGFI. Vascular functional effects of VEGFI were assessed ex vivo in mouse arteries. Cardiovascular and renal in vivo effects were studied in vatalanib-or gefitinib (EGFI [epidermal growth factor inhibitor])-treated mice. In endothelial cells, vatalanib decreased eNOS (Ser1177) phosphorylation and reduced NO and H2O2 production, responses associated with increased Nox-derived O2 - and ONOO- formation. Inhibition of Nox1/4 (GKT137831) or Nox1 (NoxA1ds), prevented vatalanib-induced effects. Nrf-2 (nuclear factor erythroid 2-related factor 2) nuclear translocation and expression of Nrf-2-regulated antioxidant enzymes were variably downregulated by vatalanib. In human vascular smooth muscles, VEGFI increased Nox activity and stimulated Ca2+ influx and MLC20 phosphorylation. Acetylcholine-induced vasodilatation was impaired and U46619-induced vasoconstriction was enhanced by vatalanib, effects normalized by N-acetyl-cysteine and worsened by L-NAME. In vatalanib-, but not gefitinib-treated mice vasorelaxation was reduced and media:lumen ratio of mesenteric arteries was increased with associated increased cardiovascular and renal oxidative stress, decreased Nrf-2 activity and downregulation of antioxidant genes. We demonstrate that inhibition of VEGF signaling induces vascular dysfunction through redox-sensitive processes. Our findings identify Noxs and antioxidant enzymes as novel targets underling VEGFI-induced vascular dysfunction. These molecular processes may contribute to vascular toxicity and hypertension in VEGFI-treated patients.

AB - Although VEGF (vascular endothelial growth factor) inhibitors (VEGFIs), are effective anticancer therapies, they cause hypertension through unknown mechanisms. We questioned whether changes in vascular redox state may be important, because VEGF signaling involves nitric oxide (NO) and reactive oxygen species. Molecular mechanisms, including NOS, NADPH oxidase (Nox)-derived reactive oxygen species, antioxidant systems, and vasoconstrictor signaling pathways, were probed in human endothelial cells and vascular smooth muscle exposed to vatalanib, a VEGFI. Vascular functional effects of VEGFI were assessed ex vivo in mouse arteries. Cardiovascular and renal in vivo effects were studied in vatalanib-or gefitinib (EGFI [epidermal growth factor inhibitor])-treated mice. In endothelial cells, vatalanib decreased eNOS (Ser1177) phosphorylation and reduced NO and H2O2 production, responses associated with increased Nox-derived O2 - and ONOO- formation. Inhibition of Nox1/4 (GKT137831) or Nox1 (NoxA1ds), prevented vatalanib-induced effects. Nrf-2 (nuclear factor erythroid 2-related factor 2) nuclear translocation and expression of Nrf-2-regulated antioxidant enzymes were variably downregulated by vatalanib. In human vascular smooth muscles, VEGFI increased Nox activity and stimulated Ca2+ influx and MLC20 phosphorylation. Acetylcholine-induced vasodilatation was impaired and U46619-induced vasoconstriction was enhanced by vatalanib, effects normalized by N-acetyl-cysteine and worsened by L-NAME. In vatalanib-, but not gefitinib-treated mice vasorelaxation was reduced and media:lumen ratio of mesenteric arteries was increased with associated increased cardiovascular and renal oxidative stress, decreased Nrf-2 activity and downregulation of antioxidant genes. We demonstrate that inhibition of VEGF signaling induces vascular dysfunction through redox-sensitive processes. Our findings identify Noxs and antioxidant enzymes as novel targets underling VEGFI-induced vascular dysfunction. These molecular processes may contribute to vascular toxicity and hypertension in VEGFI-treated patients.

KW - Endothelial cells

KW - Gefitinib

KW - Reactive oxygen species

KW - Vasodilation

KW - Vatalanib

UR - http://www.scopus.com/inward/record.url?scp=85047322525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047322525&partnerID=8YFLogxK

U2 - 10.1161/HYPERTENSIONAHA.117.10490

DO - 10.1161/HYPERTENSIONAHA.117.10490

M3 - Article

C2 - 29483228

AN - SCOPUS:85047322525

VL - 71

SP - 638

EP - 647

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 4

ER -